Jaguar Health (JAGX) received notice from the U.S. Food and Drug Administration’s Center for Veterinary Medicine on January 1 that the company has been awarded a $240,000 grant. Canalevia-CA1 is currently conditionally approved for chemotherapy-induced diarrhea in dogs. The grant will support Jaguar’s ongoing study for the treatment of CID in dogs.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAGX:
- Jaguar Health announces abstract submission for crofelemer preliminary data
- Jaguar Health Executes Strategic Stock Exchange Agreements
- Jaguar Health Announces Promising Trial Results for Crofelemer
- Jaguar Health submits request to EMA for advice on Canalevia approval plan
- Jaguar Health secures patent for crofelemer in short bowel syndrome